Matrixx Misled Shareholders About Zicam Problems, Investors Allege
This article was originally published in The Tan Sheet
Executive Summary
Shareholders in litigation against Matrixx Initiatives pending in the U.S. Supreme Court say a reasonable person's decision on whether information about a firm is important – not a statistical significance measure – should be the standard for determining when a company must reveal problems with a product.
You may also be interested in...
Search For Balance Drives Supreme Court Debate In Matrixx Case
In litigation between Matrixx Initiatives and shareholders, the Supreme Court appears concerned with striking a balance between requiring the disclosure of any facts that could affect investors' decisions and the release of so much information that important facts are obscured.
Search For Balance Drives Supreme Court Debate In Matrixx Case
In litigation between Matrixx Initiatives and shareholders, the Supreme Court appears concerned with striking a balance between requiring the disclosure of any facts that could affect investors' decisions and the release of so much information that important facts are obscured.
Search For Balance Drives Supreme Court Debate In Matrixx Case
In litigation between Matrixx Initiatives and shareholders, the Supreme Court appears concerned with striking a balance between requiring the disclosure of any facts that could affect investors' decisions and the release of so much information that important facts are obscured.